GlassScriptPhysician profile
Ariel C Hugh
NPI 1285125260
$16,617.13
in general payments reported to CMS, 2019-2025
31 companies · $7,948 in 2025
The $7,948 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,635 · 2022: $2,437 · 2023: $1,261 · 2024: $3,336 · 2025: $7,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,713 · Consulting Fee: $3,400 · Travel and Lodging: $1,414 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,712.73 |
| Consulting Fee | $3,400.00 |
| Travel and Lodging | $1,414.26 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $5,514.08 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $1,983.38 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $1,865.07 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Impulse Dynamics (USA) INC. | $1,598.63 | 2024-2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $832.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $544.56 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $542.76 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $454.69 | 2021-2025 | Lifevest |
| Abiomed | $421.40 | 2021-2025 | Impella |
| United Therapeutics Corporation | $421.24 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| E.R. Squibb & Sons, L.L.C. | $371.60 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $265.91 | 2024-2025 | Amvuttra |
| Pfizer INC. | $265.70 | 2021-2025 | |
| Scpharmaceuticals INC. | $252.93 | 2023-2025 | |
| Novo Nordisk INC | $252.39 | 2022-2025 | Ozempic, Rybelsus |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $240.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.21 | 2021-2023 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $117.13 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $113.27 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $79.41 | 2025 | General - Therapies, Cds - Mct/Cem Monitoring, Lux-Dx Insertable Cardiac Monitor |
| Bridgebio Pharma, INC. | $64.62 | 2025 | Attruby |
| Daxor Corporation | $53.02 | 2024 | Bva-100 |
| Daiichi Sankyo INC. | $39.35 | 2022-2024 | Injectafer |
| Irhythm Technologies, INC. | $37.42 | 2024 | Zio Xt Patch, Zio Monitor |
| Lantheus Medical Imaging, INC. | $34.43 | 2024 | |
| Janssen Pharmaceuticals, INC | $24.58 | 2022 | |
| Endotronix, INC. | $23.03 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Kiniksa Pharmaceuticals, LTD. | $22.60 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $21.76 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.37 | 2024 | |
| Celgene Corporation | $13.46 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Hugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.